文献速递神经肿瘤

肢端肥大症早期检测与多学科管理的最佳实践:光谱两端的挑战

Ends of the spectrum best practices for early detection and multidisciplinary management of acromegaly.
PubMed 文献 · J Neurooncol · 2024-11-28

本文综述肢端肥大症早期诊断延迟与残留肿瘤及持续共病管理两大难点,指出多数患者平均在首发症状后五年才获诊断,手术是生长激素分泌性垂体腺瘤的首选治疗,约50%患者术后需药物治疗,多学科管理可提高生化与肿瘤控制可能性。

要点

  • 多数肢端肥大症患者平均在首发症状后五年才获诊断,提高对多元临床表现的警觉可缩短诊断时间。
  • 手术是生长激素分泌性垂体腺瘤的首选治疗,但约50%患者术后需要药物治疗。
  • 生长抑素受体配体是药物治疗的基石,可单用或与多巴胺激动剂及生长激素受体拮抗剂联用。

核心结论

  • 通过针对肢端肥大症多元临床表现的教育提高认识可缩短诊断和治疗时间,专科多学科管理可提高生化与肿瘤控制的可能性。

研究设计与样本

  • 本文为小型综述,综合相关文献并呈现一例肢端肥大症病例以说明诊断和治疗决策的复杂性。

主要发现

  • 尽管生化检测方法有所改进,多数肢端肥大症患者平均在首发症状后五年才获诊断。
  • 手术是生长激素分泌性垂体腺瘤的首选治疗,可带来持久缓解,但约50%患者术后需要药物治疗。
  • 生长抑素受体配体是药物治疗的基石,可单用或与多巴胺激动剂及生长激素受体拮抗剂联用。
  • 对药物治疗下仍出现肿瘤进展者考虑再手术和放疗,罕见耐药侵袭性肿瘤需要神经肿瘤学专业知识。
  • 达到生化控制后生存率可恢复正常。

临床怎么用

  • 高怀疑指数不应仅依赖肢端增大,还应关注提示肢端肥大症的一系列表现和共病。
  • 对持续存在生化疾病者需要药物治疗,生长抑素受体配体可单用或与多巴胺激动剂及生长激素受体拮抗剂联用。
  • 对药物治疗下仍出现肿瘤进展者考虑再手术和放疗。
  • 罕见耐药侵袭性肿瘤需要神经肿瘤学专业知识。
  • 改善的药物治疗选择和对共病的仔细考量有助于个体化管理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Acromegaly is characterized by an insidious clinical presentation and delayed diagnosis. Longer delays are associated with more comorbidities which can persist after treatment of the growth hormone-secreting pituitary adenoma (GH-PA). Surgery is the primary therapy of GH-secreting PA, which can lead to durable remission. However, approximately 50% of patients require medical treatment postoperatively. Survival normalizes after achieving biochemical control. This mini-review will address ends of the spectrum challenges in acromegaly, including delayed diagnosis and management of the residual tumor and persistent comorbidities. METHODS: We synthesize relevant literature and present a case of acromegaly that highlights the complexity of clinical decision-making in the diagnosis and treatment of persistent acromegaly. RESULTS: Despite improved biochemical assays, most patients with acromegaly are diagnosed on average five years after initial symptoms. A high index of suspicion does not rely exclusively on acral enlargement, but also a constellation of manifestations and comorbidities suggestive of acromegaly. Medical therapy is required in patients with persistent biochemical disease. Somatostatin receptor ligands are the cornerstone of medical treatment and can be used alone or in combination with dopamine agonists and growth hormone receptor antagonists. Improved options of medical treatment and careful consideration of comorbidities enables individualized patient management. Reoperation and radiation are considered for tumor progression despite medical therapy. In rare cases of resistant and aggressive tumors, neuro-oncology expertise is required. CONCLUSIONS: Increased awareness through education targeting the multifaceted clinical presentation of acromegaly shortens the time to diagnosis and treatment. Multidisciplinary management by specialists increases the likelihood of biochemical and tumor control.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Cheok SK, Tavakoli-Sabour S, Beck RT, et al. Ends of the spectrum best practices for early detection and multidisciplinary management of acromegaly. J Neurooncol. 2024. PMID: 39607571. doi:10.1007/s11060-024-04833-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。